PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
143938.01
P/E exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.63. Michael Burry would check for market euphoria. Scrutinize growth expectations.
799.21
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 12.52. Jim Chanos would check for potential multiple compression risks.
77.44
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.68. Jim Chanos would check for potential asset write-down risks.
-1419.88
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -0.66. Seth Klarman would investigate cash flow improvement potential.
-6222.75
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
77.44
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.61. Jim Chanos would check for valuation bubble risks.
0.00%
Earnings yield below 50% of Drug Manufacturers - Specialty & Generic median of 0.12%. Jim Chanos would check for earnings sustainability risks.
-0.07%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.01%. Seth Klarman would investigate cash flow improvement potential.